Evidence map›Paper›PMID 37285880›Full record

ArticleInternational journal of biological macromolecules2023

Preparation of injectable hydrophilic dextran/AgNPs nanocomposite product: White light active biomolecules as an antitumor agent.

Ulviye Bunyatova, Manel Ben Hammouda, Jennifer Y Zhang

Abstract read
In one paragraph

Article in International journal of biological macromolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ulviye BunyatovaBiomedical Department, Engineering Facility, Baskent UniversityAnkara, Turkey; Department of Electrical and Computer Engineering, Duke University, Pratt School of Engineering, Durham, NC, USA. Electronic address: bunyatovau@yahoo.com.
Manel Ben HammoudaDepartment of Dermatology, Duke University, School of Medicine, Durham, NC, USA.
Jennifer Y ZhangDepartment of Dermatology, Duke University, School of Medicine, Durham, NC, USA; Department of Pathology, Duke University, School of Medicine, Durham, NC, USA.

Funding

UBE2N/UBE2V1 as a vulnerable link between keratinocytes and myeloid cellsR01AR073858 · NIAMS · DUKE UNIVERSITY · PI Jennifer Yunyan Zhang · 2019 to 2026
$2.1M
THE ROLE OF MALT1 IN MELANOMA GROWTH AND METASTASISR03CA188619 · NCI · DUKE UNIVERSITY · PI ZHANG, JENNIFER YUNYAN · 2015 to 2016
$159k
NCI NIH HHS R03 CA188619NIAMS NIH HHS R01 AR073858
6 · The paper itself

Abstract

Incidence of various cancers including melanoma continues to rise worldwide. While treatment options have expanded in the recent years, the benefit of these treatments suffer from short period of duration for many patients. Hence, new treatment options are highly desired. Here, we propose a method combining a Dextran/reactive-copolymer/AgNPs nanocomposite and a harmless visible light approach to obtain a plasma substitute carbohydrate-based nanoproduct (D@AgNP) that shows strong antitumor activity. Light-driven polysaccharide-based nanocomposite provided essential conditions for extra small (8-12nm) AgNPs capping with subsequent specific self-assembly into spherical-like cloud nanostructures. Obtained biocompatible D@AgNP are stable over six months at room temperature and demonstrated absorbance peak at 406 nm. New formulated nanoproduct revealed efficient anticancer properties against A375 with IC50 0.0035 mg/mL following 24-h incubation; complete cell death is achieved at 0.001 mg/mL and 0.0005 mg/mL by 24- and 48-h time points, respectively. SEM examination shows that D@AgNP altered the shape of the cell structure and damaged the cell membrane. TEM finding shows that D@AgNP are mostly localized at vesicles such as the endosomes, lysosomes and mitochondria. It is anticipated that the introduced new method serves as the cornerstone for improving the generation of biocompatible hydrophilic carbohydrate-based anticancer drugs.

Indexed as

Antineoplastic AgentsMetal NanoparticlesNanocompositesAnti-Bacterial AgentsDextransHumansLightAnti-Bacterial AgentsAntineoplastic AgentsDextransAntitumor efficiencyDextranMelanoma cellsPlasma substitute polysaccharidesSilver nanoparticles

Identifiers

PMID37285880
PMCPMC11037523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.